Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T/CAR-NK cells in recurrent/unresectable solid tumors
NCT06572956Phase 1Active, not recruiting
- Sponsor
- Second Hospital of Shandong University
- Start
- Mar 2024
- Primary completion
- Mar 2025
- Modality
- CAR-T Cells, Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD19 CAR-T + CD19 CAR-NK in solid tumor, sponsored by Second Hospital of Shandong University. Primary endpoints: Objective Response Rate and Progression-Free Survival. Started Mar 2024; status: active, not recruiting.
02
Drugs
CD19 CAR-T + CD19 CAR-NK
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06572956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06572956.